Skip to main content

Resetting the tumor microenvironment to favor anti-tumor immunity after local ablation.

Publication ,  Conference
Nief, CA; Agudogo, JS; Gonzales, A; Previs, RA; Nair, SK; Ramanujam, N
Published in: Journal of Clinical Oncology
May 20, 2021

2561 Background: Percutaneous tumor ablation is a non-surgical method of tumor destruction that leaves necrotic tumor debris in situ. Tumor associated antigens released after ablation have the potential to initiate a systemic anti-tumor immune response, however the hostile tumor microenvironment hinders antigen presentation and T cell activity. We hypothesized that resetting the tumor microenvironment with oral sodium bicarbonate to decrease tumor acidity and low-dose cyclophosphamide to deplete pro-tumor immune cells would improve the ability of ablation to initiate anti-tumor immunity. Methods: Tumor growth, overall survival, and metastatic burden was assessed in orthotopic tumor models of triple-negative breast cancer (67NR, 4T1, and E0771). Tumor ablation was performed on palpable tumors using percutaneous ethanol injection (PEI) with 6% ethylcellulose to improve retention in the tumor. Surgical excision was used as a negative control to test the role of in situ tumor debris. Before ablation mice were placed on 200 mM of sodium bicarbonate (SB) in their drinking water and received a single intraperitoneal injection of 200 mg/kg of cyclophosphamide (CP). Mice surviving to 60 days after tumor implant without a primary tumor or signs of metastases were considered "cured" and re-challenged with 50e5 tumor cells in the contralateral mammary pad. T cell dependance was assessed with in vivo CD8 depletions. Results: The combination of PEI+SB+CP produced a potent anti-tumor response, curing a majority of mice (5/7 of E0771, 8/12 of 67NR, 7/12 of 4T1). No mice were cured using PEI alone, SB alone, CP alone, or any combination of two therapies (0/51 of E0771, 0/73 of 67NR, 0/75 of 4T1,). Re-challenge tumor growth was hindered in mice cured with PEI+SB+CP. Mice receiving PEI+SB+CP had significantly less metastases and lived longer than mice receiving surgical excision alone or surgical excision with SB+CP. Additionally the anti-metastatic response of PEI+SB+CP was undone when CD8+ T cells were depleted. Conclusions: Here the anti-tumor response of local ablation produced by PEI was enhanced by priming the tumor with low-dose CP and oral SB in metastatic breast cancer. These results suggest that tumor ablation with CP and SB can create a T cell dependent, personalized immune response to a tumor using only low-cost, easily accessible supplies, and the host’s own tumor.

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2021

Volume

39

Issue

15_suppl

Start / End Page

2561 / 2561

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Nief, C. A., Agudogo, J. S., Gonzales, A., Previs, R. A., Nair, S. K., & Ramanujam, N. (2021). Resetting the tumor microenvironment to favor anti-tumor immunity after local ablation. In Journal of Clinical Oncology (Vol. 39, pp. 2561–2561). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2021.39.15_suppl.2561
Nief, Corrine A., Júlia Sroda Agudogo, Alana Gonzales, Rebecca A. Previs, Smita K. Nair, and Nimmi Ramanujam. “Resetting the tumor microenvironment to favor anti-tumor immunity after local ablation.” In Journal of Clinical Oncology, 39:2561–2561. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.2561.
Nief CA, Agudogo JS, Gonzales A, Previs RA, Nair SK, Ramanujam N. Resetting the tumor microenvironment to favor anti-tumor immunity after local ablation. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2021. p. 2561–2561.
Nief, Corrine A., et al. “Resetting the tumor microenvironment to favor anti-tumor immunity after local ablation.Journal of Clinical Oncology, vol. 39, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2021, pp. 2561–2561. Crossref, doi:10.1200/jco.2021.39.15_suppl.2561.
Nief CA, Agudogo JS, Gonzales A, Previs RA, Nair SK, Ramanujam N. Resetting the tumor microenvironment to favor anti-tumor immunity after local ablation. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2021. p. 2561–2561.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2021

Volume

39

Issue

15_suppl

Start / End Page

2561 / 2561

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences